Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.
Our library stands out due to several important features:
partner
Reaxense
upacc
P55265
UPID:
DSRAD_HUMAN
Alternative names:
136 kDa double-stranded RNA-binding protein; Interferon-inducible protein 4; K88DSRBP
Alternative UPACC:
P55265; B1AQQ9; B1AQR0; D3DV76; O15223; O43859; O43860; Q9BYM3; Q9BYM4
Background:
The Double-stranded RNA-specific adenosine deaminase, also known as Interferon-inducible protein 4, plays a crucial role in A-to-I RNA editing. This process involves the hydrolytic deamination of adenosine to inosine in double-stranded RNA, impacting gene expression and function through various mechanisms such as mRNA translation, pre-mRNA splicing, and RNA stability. Its editing capabilities extend to both viral and cellular RNAs, influencing the functional activities of proteins and the genetic stability of RNA virus genomes.
Therapeutic significance:
Linked to diseases like Dyschromatosis symmetrica hereditaria and Aicardi-Goutieres syndrome 6, this protein's unique function in RNA editing and virus replication modulation highlights its potential as a target for therapeutic intervention. Understanding the role of Double-stranded RNA-specific adenosine deaminase could open doors to potential therapeutic strategies, especially in genetic and viral diseases.